3 PROGRESS DURING THE CURRENT FUNDING PERIOD 4 PROGRAM LEADERSHIP 5 PROGRAM AS AN INTEGRATED EFFORT 5 COLLABORATING INSTITUTIONS 5 PROJECT AND CORE SUMMARIES OF DISCUSSION 5 PROTECTION OF HUMAN SUBJECTS (Resume) 8 VERTEBRATE ANIMALS (Resume) 8 ADDITIONAL REVIEW CONSIDERATIONS 8 BUDGETARY OVERLAP 8 PROJECT 1: Mediators of Lung Adenocarcinoma Metastasis 9 PROJECT 2: Targeting the ERK Pathway in KRAS-and BRAF-Driven Lung Cancers 15 PROJECT 3: Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lung Cancer 23 PROJECT 4: Lung Cancer Drivers and Dependencies as Therapeutic Targets 31 CORE A: Molecular Profiling and Pathology 39 CORE B: Biostatistics and Bioinformatics 44 CORE C: Administration 49 COMMITTEE BUDGET RECOMMENDATIONS 53 SPECIAL EMPHASIS PANEL ROSTER DESCRIPTION (provided by applicant): Since molecular events underlie clinical events, we hypothesize that unraveling mechanisms of intracellular signaling and metastasis in lung cancers will lead to the identification of targets for therapy for these illnesses and for individul patients. Our roles in the development of EGFR and ALK kinase inhibitors and the discoveries that mutations in EGFR and KRAS genes and ALK re-arrangements underlie sensitivity and resistance to these agents have demonstrated the practicality and potential of this approach. We propose 4 research projects and 3 cores built on an iterative research process uniting clinical and laboratory observations that have linked mutations in tumors to improved outcomes in patients. This grant embraces investigators, technologies, and pathways, each focused by a specific clinical question, proposing to identify targets for therapies in lung cancers. Project 1 ill characterize mediators of metastasis in lung cancers that can serve as targets for intervention. Project 2 attacks "pan-refractory" KRAS-driven tumors by targeting ERK and its feedback inhibition of upstream signaling in KRAS- and BRAF-driven lung cancers. RP3 will investigate mechanisms and modulators of sensitivity and resistance to EGFR inhibitors, elucidating the role of HER2 and identifying the intrinsic regulatory domains of EGFR-mutant kinases required for function. Project 4 uses innovative mouse models and RNA interference to interrogate lung cancer biology and therapy, focusing on "gain of function" p53 mutations and oncogenic drivers on 8p that cooperate with EGFR and KRAS mutations. Our Molecular Profiling &Pathology Core crystallizes nearly a decade of experience in specimen collection, precise pathologic characterization in mouse and annotated human samples, mutation testing, and gene profiling in lung cancers to enrich and support each project. The Biostatistics and Bioinformatics Core ensures consistency in biostatistical analyses, unifies information exchange, and provides projects with additional analytic capabilities. The Administration Core facilitates communication and dissemination of findings and provides the forum for the PIs and the Executive and Scientific Advisory Committees to ensure rigorous scientific review and reassessment of priorities.
Lung cancers are America's leading cancer killers, responsible for 158,000 deaths this year. This grant addresses the two most critical roadblocks to improving the care and curability of persons with these illnesses: (1) understanding how cancers spread (metastasis) and (2) the lack of highly effective medicines to prevent spread or to eradicate cancers that have spread from the lung.
|Chen, Qing; Boire, Adrienne; Jin, Xin et al. (2016) Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533:493-8|
|Hames, Megan L; Chen, Heidi; Iams, Wade et al. (2016) Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancerâ˜†. Lung Cancer 92:29-34|
|Amato, Katherine R; Wang, Shan; Tan, Li et al. (2016) EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res 76:305-18|
|Lito, Piro; Solomon, Martha; Li, Lian-Sheng et al. (2016) Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351:604-8|
|Malladi, Srinivas; Macalinao, Danilo G; Jin, Xin et al. (2016) Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165:45-60|
|Konduri, Kartik; Gallant, Jean-Nicolas; Chae, Young Kwang et al. (2016) EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov 6:601-11|
|Dragani, Tommaso A; Castells, Antoni; Kulasingam, Vathany et al. (2016) Major milestones in translational oncology. BMC Med 14:110|
|Manchado, Eusebio; Weissmueller, Susann; Morris 4th, John P et al. (2016) A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534:647-51|
|Johnson, Douglas B; Estrada, Monica V; Salgado, Roberto et al. (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7:10582|
|MassaguÃ©, Joan; Obenauf, Anna C (2016) Metastatic colonization by circulating tumour cells. Nature 529:298-306|
Showing the most recent 10 out of 157 publications